secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2024-07-29T23:59:59+00:00
Accession:  0001193125-24-186674
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health's Shield blood test gets FDA approval for colorectal cancer screening in ages 45+
--------------------------------------------------------------------------------

- Shield is first blood test approved by FDA as a primary screening option for colorectal cancer.
- Meets CMS requirements for Medicare coverage; expected to be covered for eligible Medicare beneficiaries.
- ECLIPSE study showed 83% sensitivity for CRC detection and 90% specificity for advanced neoplasia.
- Real-world adherence rate for Shield is over 90%, compared to 28-71% for other screening methods.
- Company to launch test soon; commercial insurance coverage expected after future guideline inclusion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000119312524186674/0001193125-24-186674-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000119312524186674/d869952d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-186674

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer